THE SHORT ANSWER: In June 2026, federal regulators asked manufacturers to update testosterone product labels: drop the old warning that the drug was never proven for age-related low testosterone, narrow the prostate cancer contraindication to metastatic disease only, and shift benign prostatic hyperplasia from a warning to a monitoring recommendation. One month later, the Endocrine Society issued a statement pulling in a different direction. It reaffirmed that a diagnosis still requires two separate early-morning fasting blood draws, that symptoms by themselves diagnose nothing, and that men with a BMI over 27 should address weight before considering replacement. Both things are true at once. The safety picture improved. The diagnostic bar did not move. If you are tired, foggy, and losing strength, the label change does not make testosterone your answer. It makes an accurate workup more valuable, not less.
What did the FDA actually change in 2026?
On June 18, 2026, HHS announced that FDA had requested three specific label revisions for testosterone products: remove the "limitation of use" statement saying safety and effectiveness had not been established for age-related hypogonadism; update prostate cancer language so testosterone is contraindicated only in men with metastatic prostate cancer; change benign prostatic hyperplasia from a warning against use to a recommendation to monitor, because clinical data did not show worsening in mild-to-moderate cases.
The evidence behind the change is largely the TRAVERSE trial, a randomized study of more than 5,200 men with hypogonadism who already had cardiovascular disease or were at high risk for it. Testosterone was noninferior to placebo for major adverse cardiac events over a median follow-up of roughly two years (Lincoff et al., NEJM 2023, PubMed record).
That is a meaningful result. For two decades, cardiovascular risk was the loudest objection to testosterone therapy, and the largest trial designed to test it did not find the signal people feared.
What did not change?
Three things, and they matter more to most men than the label revision does.
The diagnosis still requires labs, not symptoms. The Endocrine Society's July 16, 2026 statement is direct about this: at least two early-morning, fasting total testosterone measurements, with a common clinical threshold near 300 ng/dL, and reversible causes ruled out first. Their language is that symptoms alone are not diagnostic.
The assay still has to be trustworthy. The same statement pushes for assays certified through the CDC's Hormone Standardization Program, because non-standardized testosterone tests can return meaningfully different numbers from the same blood sample. A single mid-afternoon draw run on an uncertified assay is not a diagnosis. It is a data point with a wide error bar.
Some risks are still on the table. TRAVERSE was reassuring on heart attack and stroke. It was not clean across the board. Secondary findings included a roughly 50 percent relative increase in pulmonary embolism and higher fracture rates in the testosterone group. Long-term prostate cancer risk remains unestablished. The Endocrine Society's conclusion is that pre-treatment risk assessment and ongoing monitoring stay essential.
Why do so many men get a "low" result that isn't true hypogonadism?
This is the part the direct-to-consumer telehealth market tends to skip, and it is the single most common thing we see in lab review at our clinic.
Testosterone travels through the blood mostly bound to sex hormone-binding globulin, or SHBG. Obesity, hyperinsulinemia, and fatty liver all drive SHBG down. When SHBG drops, total testosterone drops with it, because you are measuring the bound pool along with the free pool. If LH and FSH come back normal alongside that low total testosterone, the pituitary is not signaling for more, which suggests the testes are working fine.
Endocrinologists have a name for this pattern: pseudo-hypogonadism of obesity. A 2025 review in the Journal of Clinical Endocrinology & Metabolism walks through a case where a man went from 118 kg to 94 kg, about 20 percent of his body weight, and his testosterone rose from 147 ng/dL to 467 ng/dL. No testosterone prescription. Weight loss did it (Muir, Wittert, Handelsman, JCEM 2025, PubMed record).
Sleep is the other big one. Testosterone is released in pulses tied to sleep architecture, and untreated obstructive sleep apnea disrupts exactly that. The relationship between sleep apnea, obesity, and low testosterone is tangled enough that treating the hormone without addressing the sleep can leave the actual problem in place (Bercea et al., 2023, PubMed record).
So when a man in his forties tells us he is exhausted, soft in the middle, and unmotivated, the honest answer is that low testosterone is one candidate on a list that also includes untreated apnea, insulin resistance, thyroid dysfunction, iron deficiency, chronic under-recovery from training, and a medication side effect. Sorting that out is a testing question, not a prescribing question. normal labs and optimal ranges are not the same thing.
What does a proper low testosterone workup look like?
Here is the sequence we use at Vitality Dartmouth. Justin Coelho, RN, BSN, builds and runs the program side. A nurse practitioner orders labs and prescribes, and a physician serves as medical director. Nothing gets prescribed off a symptom questionnaire.
- Two early-morning, fasted total testosterone draws, usually before 10 a.m., on separate days. One number is noise. Two agreeing numbers are a signal.
- SHBG and albumin, so a low total can be interpreted rather than taken at face value.
- LH and FSH, to separate a testicular problem from a pituitary or hypothalamic one, or from the functional pattern described above.
- Prolactin and a morning cortisol when the pattern suggests a central cause.
- Metabolic context: fasting insulin, HbA1c, a full lipid panel with ApoB, hs-CRP, comprehensive metabolic panel, ferritin, vitamin D, and a full thyroid panel.
- Hematocrit and PSA at baseline for any man who may become a candidate, because both need monitoring on therapy.
- A sleep screen, with referral for a sleep study when the history points that way.
- A conversation about what you actually want. Strength, body composition, energy, libido, and fertility do not all respond the same way, and exogenous testosterone suppresses sperm production. That matters if you are not done having kids.
Layered on top, our genomic and lab biomarker testing adds context on how you handle inflammation, methylation, lipid processing, and recovery. DNA does not diagnose low testosterone. It does help explain why two men with the same lab values feel and respond differently, and it shapes the nutrition and training plan built around the medical piece.
If weight is driving it, what comes first?
For a man with a BMI over 27 and no evidence of a pituitary or testicular disease, the Endocrine Society's position is that weight loss is first-line, not testosterone.
That is not a brush-off. It is the higher-yield intervention. The JCEM case above is one example, and the general pattern in that literature is that meaningful fat loss raises testosterone in men whose low reading is metabolically driven.
Our medically supervised weight loss program is built for that: provider-prescribed GLP-1 medication where appropriate, protein targets set high enough to protect lean mass, resistance training programmed around the medication, and repeat labs so you can see whether the underlying picture is actually moving. For screened candidates, our providers also discuss retatrutide, a triple-hormone-receptor agonist that produced up to 30.3 percent mean weight loss at 104 weeks in Lilly's Phase 3 TRIUMPH-1 trial. Retatrutide is investigational and has not been approved by the FDA for any use. Any discussion of it happens one-on-one with a licensed prescriber who reviews the evidence, the unknowns, and the alternatives with you. compare the current options in more detail.
If a man loses 30 pounds, sleeps through the night, and his testosterone climbs from 240 to 480, he never needed a prescription. If he does all of that and it stays at 240, now we have a clean answer and a clear reason to talk to a prescriber about therapy.
Is testosterone therapy ever the right call?
Yes. Men with confirmed hypogonadism from disease affecting the testes, pituitary, or hypothalamus, who meet the diagnostic criteria and have had reversible causes addressed, are exactly who the therapy exists for. The 2026 label update makes that conversation less encumbered than it was, particularly for older men and for men with mild-to-moderate prostate enlargement who were previously waved off.
What the label change does not do is turn testosterone into a general-purpose energy and vitality product. Individual responses vary, and no legitimate program can promise a specific outcome. Anyone offering a prescription after a single afternoon blood draw and a symptom checklist is selling convenience, not care.
Frequently asked questions from Dartmouth and the SouthCoast
Where can I get testosterone testing near Dartmouth, MA?
Vitality Dartmouth serves Dartmouth, New Bedford, Westport, Fairhaven, Fall River, and the surrounding SouthCoast. We order comprehensive hormone and metabolic panels through standard commercial labs with local draw sites, then sit down and walk you through what the numbers mean rather than emailing a PDF.
Do you prescribe testosterone?
Justin is an RN and does not prescribe or order labs. Prescribing and lab orders come from our nurse practitioner, under a physician medical director. That structure is the point. It is also why we will tell you when the answer is not a prescription.
Why two morning blood draws instead of one?
Testosterone follows a daily rhythm, peaking in the morning and falling through the day, and it varies day to day. A single draw taken at the wrong hour can misclassify a man in either direction. Two early-morning fasted draws is the standard the Endocrine Society reaffirmed in 2026.
I already had a low result from an online provider. Do I need to start over?
Not necessarily. Bring us the report. We will look at when it was drawn, what assay ran it, and whether SHBG, LH, and FSH were included. Often the gap is that the panel was too narrow to interpret, and we fill it in rather than repeat everything.
Ready to figure out what is actually going on?
If you are in Dartmouth, New Bedford, Westport, Fairhaven, Fall River, or anywhere on the SouthCoast and you have been wondering whether your symptoms are hormonal, metabolic, or something else, start with a free 15-minute Metabolic Discovery Call. We will talk through your history, what testing would actually answer your question, and what a program would look like. No labs or scans are included on that call. It is a conversation.
Vitality Dartmouth · 668 State Rd, Dartmouth, MA 02747 · (774) 249-0230
This article is for general educational purposes and does not constitute medical advice, diagnosis, or treatment, and it does not create a clinician-patient relationship. Testosterone therapy is a prescription treatment that carries risks and is not appropriate for everyone. Retatrutide is an investigational drug that has not been approved by the FDA for any use; it is discussed here as clinical trial information. Individual results vary, and no outcome is guaranteed. Talk with a qualified healthcare provider about your own situation before starting, stopping, or changing any therapy. All programs at Vitality Dartmouth are RN-led and physician-supervised, with prescribing and lab orders handled by a licensed prescriber.